Hypertension, antihypertensive medication use, and risk of psoriasis

JAMA Dermatology

Volumn 150, Issue 9, 2014, Pages 957-963

  Wu, Shaowei ^a,b   Han, Jiali ^b,c   Li, Wen Qing ^a   Qureshi, Abrar A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; DISEASE DURATION; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; PSORIASIS; RISK FACTOR; CHEMICALLY INDUCED; DRUG ERUPTIONS; MIDDLE AGED; RISK ASSESSMENT;

ANTIHYPERTENSIVE AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RISK ASSESSMENT;

EID: 84908227493     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.9957     Document Type: Article

References (33)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
2. LowesMA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
3. Schon MP, Boehncke WH. Psoriasis. N Engl JMed. 2005;352(18):1899-1912.
4. Patel RV, Lebwohl M. In the clinic: psoriasis. Ann Intern Med. 2011;155(3):ITC-21-ITC2-15.
5. Javitz HS,Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J AmAcad Dermatol. 2002;46(6):850-860.
6. Gelfand JM, Neimann AL, Shin DB,Wang X, Margolis DJ, Troxel AB. Risk ofmyocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735-1741.
7. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411-2418.
8. LiWQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S.women: a cohort study. Br J Dermatol. 2012;166(4):811-818.
9. Armesto S, Coto-Segura P, Osuna CG, Camblor PM, Santos-Juanes J. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol. 2012;26(6):785-788.
10. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6 (3):e18227. doi:10.1371/journal.pone.0018227.
11. Cohen AD, SherfM, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and themetabolic syndrome: a cross-sectional study. Dermatology. 2008;216(2): 152-155.
12. Cohen AD,Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010;90(1):23-26.
13. Neimann AL, Shin DB,Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J AmAcad Dermatol. 2006;55(5):829-835.
14. Sommer DM, Jenisch S, Suchan M, Christophers E,Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7): 321-328.
15. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379-382.
16. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008;158(6):1299-1307.
17. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299-303.
18. Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol. 2001;81(5):347-349.
19. Waqar S, Sarkar PK. Exacerbation of psoriasis with blocker therapy. CMAJ. 2009;181(1-2):60. doi:10.1503/cmaj.081433.
20. Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S; French Society of Dermatology. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology. 2009;218 (2):103-109.
21. Milavec-Pureti V, Mance M, Ceovi R, Lipozeni J. Drug induced psoriasis. Acta Dermatovenerol Croat. 2011;19(1):39-42.
22. Dominguez PL, Assarpour A, Kuo H, Holt EW, Tyler S, Qureshi AA. Development and pilot-testing of a psoriasis screening tool. Br J Dermatol. 2009; 161(4):778-784.
23. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123 (5):894-900.
24. Austin LM, Ozawa M, Kikuchi T,Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon, interleukin-2, and tumor necrosis factor, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113(5):752-759.
25. SergM, Kampus P, Kals J, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012;72(5):427-432.
26. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29(5):543-548.
27. Lakoski SG, Cushman M, Siscovick DS, et al. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens. 2011;25(2):73-79.
28. Zhang Y, Thompson AM, TongW, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China. J Hypertens. 2010;28(1):35-40.
29. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007; 25(6):606-615.
30. O'BrienM, Koo J. The mechanism of lithium and blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5(5):426-432.
31. Ockenfels HM, Nussbaum G, Schultewolter T, Mertins K,Wagner SN, Goos M. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology. 1995;191(3):217-225.
32. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated? understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32-38.
33. LiW, Han J, Hu FB, Curhan GC, Qureshi AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol. 2012;132(2):291-298.